Pan-COVID
Pan-COVID
SNS812 belong to a class of nucleic acid medicines called siRNA that uses a gene silencing mechanism (RNA interference, RNAi) to specifically cleave a highly conserved region of SARS-CoV-2 genome and thereby, inhibiting virus replication, and eliminating viruses in cells.
Vaccines and antibodies currently on the market target the most mutated viral spike protein, which is easily escaped by the virus, leading to vaccine breakthroughs and repeated outbreaks of epidemics. SNS812 targets highly-conserved regions of the virus, and is expected to solve the problems of SARS-CoV-2 variants.
According to the statistics of market analysis agencies, the COVID-19 preventive and therapeutic drug market is 150 billion (IQVIA Holdings) and 25.6 billion US dollars (IncInsightAce Analytic) respectively. SNS812 is currently one of the few drug candidates in the world that can target broad-spectrum of SARS-COV-2 variants.
Research Code | Therapeutic Area | Indication | Pre-Clinical | Phase I | Phase II | Phase III | NDA | Market | More |
---|
SNS812 is a first-in-class siRNA new drug for COVID-19 infection. It specifically targets the highly conserved region of SARS-COV-2 genome to inhibit virus replication and eliminate viruses in cells.
建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?